Lymecycline
As of the edition of 20 October 2026, Lymecycline is a small molecule: marketed, first approved in 1992 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Tetralysal
- First approved
- 17 July 1992 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Galderma Brasil Ltda; 2 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Galderma Brasil Ltda | Applicant | 1999 to now |